Lung cancer international最新文献

Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer. 肾素-血管紧张素系统成分及其相关酶在肺癌中的基因表达变化。

Lung cancer international Pub Date : 2017-01-01 Epub Date: 2017-07-16 DOI: 10.1155/2017/6914976

Benjamin Goldstein, Malav Trivedi, Robert C Speth

{"title":"Alterations in Gene Expression of Components of the Renin-Angiotensin System and Its Related Enzymes in Lung Cancer.","authors":"Benjamin Goldstein, Malav Trivedi, Robert C Speth","doi":"10.1155/2017/6914976","DOIUrl":"https://doi.org/10.1155/2017/6914976","url":null,"abstract":"Objectives: The study assessed the existence and significance of associations between the expression of fifteen renin-angiotensin system component genes and lung adenocarcinoma.Materials and methods: NCBI's built-in statistical tool, GEO2R, was used to calculate Student's t-tests for the associations found in a DNA expression study of adenocarcinoma and matched healthy lung tissue samples. The raw data was processed with GeneSpring™ and then used to generate figures with and without Sidak's multiple comparison correction.Results: Ten genes were found to be significantly associated with adenocarcinoma. Seven of these associations remained statistically significant after correction for multiple comparisons. Notably, AGTR2, which encodes the AT2 angiotensin II receptor subtype, was significantly underexpressed in adenocarcinoma tissue (p < 0.01). AGTR1, ACE, ENPEP, MME, and PRCP, which encode the AT1 angiotensin II receptor, angiotensin-converting enzyme, aminopeptidase N, neprilysin, and prolylcarboxypeptidase, respectively, were also underexpressed. AGT, which encodes angiotensinogen, the angiotensin peptide precursor, was overexpressed in adenocarcinoma tissue.Conclusion: The results suggest an association between the expression of the genes for renin-angiotensin system-related proteins and adenocarcinoma. While further research is necessary to conclusively demonstrate a link between the renin-angiotensin system and lung cancers, the results suggest that the renin-angiotensin system plays a role in the pathology of adenocarcinoma.","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2017 ","pages":"6914976"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/6914976","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35306242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. 细胞学取样对III-IV期肺腺癌EGFR突变检测的影响。

Lung cancer international Pub Date : 2017-01-01 Epub Date: 2017-03-07 DOI: 10.1155/2017/9614938

Rhian Siân Davies, Christian Smith, Gwenllian Edwards, Rachel Butler, Diane Parry, Jason Francis Lester

{"title":"Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.","authors":"Rhian Siân Davies, Christian Smith, Gwenllian Edwards, Rachel Butler, Diane Parry, Jason Francis Lester","doi":"10.1155/2017/9614938","DOIUrl":"https://doi.org/10.1155/2017/9614938","url":null,"abstract":"Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis. Methods. The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result. Results. Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway. Conclusions. In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2017 ","pages":"9614938"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9614938","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34877250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Life Expectancy in Pleural and Peritoneal Mesothelioma. 胸膜和腹膜间皮瘤的预期寿命。

Lung cancer international Pub Date : 2017-01-01 Epub Date: 2017-01-23 DOI: 10.1155/2017/2782590

Robert Shavelle, Kate Vavra-Musser, Jessica Lee, Jordan Brooks

引用次数: 40

Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge 智障人士肺癌诊断和治疗的挑战:目前的知识状况

Lung cancer international Pub Date : 2016-09-26 DOI: 10.1155/2016/6787648

D. Satgé, E. Kempf, J. Dubois, M. Nishi, J. Trédaniel

{"title":"Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge","authors":"D. Satgé, E. Kempf, J. Dubois, M. Nishi, J. Trédaniel","doi":"10.1155/2016/6787648","DOIUrl":"https://doi.org/10.1155/2016/6787648","url":null,"abstract":"As the life expectancy of people with intellectual disability (ID) has progressed, they have become similarly at risk of cancer as individuals of the general population. Epidemiological studies indicate a reduced incidence and mortality from lung cancer in the total population of persons with ID. However, the pattern is heterogeneous and the risk is strongly correlated with the impairment level; persons with mild intellectual impairment have higher cancer risk, and this subgroup also has the highest tobacco consumption (the major risk factor for lung cancer) compared to individuals with more severe impairment. Clinical presentation of lung cancer in persons with ID is often atypical, with symptoms frequently hidden by the mental state and communication impairments. Treatment can be impeded by incomplete understanding and lack of cooperation on the part of the patient; nevertheless, general principles for treating lung cancer must be applied to persons with ID. Early diagnosis and implementation of an adapted treatment plan may result in lung cancer outcomes similar to those of individuals in the general population. Physicians facing the difficult task of treating lung cancer in persons with ID are called to carry out their mission of care in a responsible, free, and creative way.","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86798713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors. 高剂量率近距离放疗作为支气管内肿瘤的一种治疗选择。

Lung cancer international Pub Date : 2016-01-01 Epub Date: 2016-07-14 DOI: 10.1155/2016/3086148

Ali Hosni, Andrea Bezjak, Alexandra Rink, Kasia Czarnecka, Andrew McPartlin, Susan Patterson, Elantholiparameswaran Saibishkumar

{"title":"High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors.","authors":"Ali Hosni, Andrea Bezjak, Alexandra Rink, Kasia Czarnecka, Andrew McPartlin, Susan Patterson, Elantholiparameswaran Saibishkumar","doi":"10.1155/2016/3086148","DOIUrl":"https://doi.org/10.1155/2016/3086148","url":null,"abstract":"Purpose. To report our experience with high dose rate endobronchial brachytherapy (HDR-EBBT) and to assess its efficacy and tolerability with possibility of its use in selected cases with curative intent. Method. Retrospective review of patients with endobronchial tumors treated at our institution in 2007-2013 with HDR-EBBT. Subjective response and treatment related toxicity were extracted from patients' records. Clinical response was evaluated by chest CT +/- bronchoscopy 2-3 months after treatment. Local control (LC) and overall survival (OS) were analyzed. Results. Overall 23 patients were identified. Ten patients were treated with curative intent, in 8 of them HDR-EBBT was combined with external beam radiotherapy. Short term palliation was as follows: dyspnea (13/15), cough (12/14), and hemoptysis (3/3). Seventeen patients were evaluated, of whom 9 (53%) showed complete response. Four patients developed local failure (only 1 of them treated with curative intent) and were salvaged with HDR-EBBT (n = 1), chemotherapy (n = 2), and laser (n = 1). Among patients treated with curative intent, the 2-year LC and OS were 89% and 67%, respectively, and 2 out of 4 deaths were cancer-related. Late toxicity included bronchial stenosis (n = 1). Only 1 patient had fatal hemoptysis and postmortem examination indicated local recurrence. Conclusion. HDR-EBBT is promising treatment with tolerable complication if used in properly selected patients. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2016 ","pages":"3086148"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/3086148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34344622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

A Simple and Safe Technique for CT Guided Lung Nodule Marking prior to Video Assisted Thoracoscopic Surgical Resection Revisited 再谈一种简单安全的CT引导下胸腔镜手术切除前肺结节标记技术

Lung cancer international Pub Date : 2015-10-22 DOI: 10.1155/2015/235720

J. Stephenson, Ayman Mahfouz, S. Rathinam, A. Nakas, A. Bajaj

引用次数: 18

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. 铂和叶酸联合抗代谢物化疗时代的恶性胸膜间皮瘤预后。

Lung cancer international Pub Date : 2015-01-01 Epub Date: 2015-03-02 DOI: 10.1155/2015/590148

Mathieu D Saint-Pierre, Christopher Pease, Hamid Mithoowani, Tinghua Zhang, Garth A Nicholas, Scott A Laurie, Paul Wheatley-Price

{"title":"Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.","authors":"Mathieu D Saint-Pierre, Christopher Pease, Hamid Mithoowani, Tinghua Zhang, Garth A Nicholas, Scott A Laurie, Paul Wheatley-Price","doi":"10.1155/2015/590148","DOIUrl":"https://doi.org/10.1155/2015/590148","url":null,"abstract":"Introduction. Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. Palliative platinum-based chemotherapy may help to improve symptoms and prolong life. Since 2004, the platinum is commonly partnered with a folate antimetabolite. We performed a review investigating if survival had significantly changed before and after the arrival of folate antimetabolites in clinical practice. Methods. All MPM patients from January 1991 to June 2012 were identified. Data collected included age, gender, asbestos exposure, presenting signs/symptoms, performance status, histology, stage, bloodwork, treatment modalities including chemotherapy, and date of death or last follow-up. The primary endpoint was overall survival. Cox models were applied to determine variables associated with survival. Results. There were 245 patients identified. Median overall survival for all patients was 9.4 months. After multivariate analysis, performance status, stage, histology, leucocytosis, and thrombophilia remained independently associated with survival. Among all patients who received chemotherapy, there was no difference in overall survival between the periods before and after folate antimetabolite approval: 14.2 versus 13.2 months (P = 0.35). Specifically receiving combined platinum-based/folate antimetabolite chemotherapy did not improve overall survival compared to all other chemotherapy regimens: 14.1 versus 13.6 months (P = 0.97). Conclusions. In this review, we did not observe an incremental improvement in overall survival after folate antimetabolites became available. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2015 ","pages":"590148"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/590148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34026355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery. 围手术期β受体阻滞剂对慢性阻塞性肺疾病肺切除术患者肺部并发症的影响

Lung cancer international Pub Date : 2015-01-01 Epub Date: 2015-09-01 DOI: 10.1155/2015/204826

A Kamath, D E Stover, A Hemdan, I Belinskaya, R M Steingart, Y Taur, M B Feinstein

{"title":"Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery.","authors":"A Kamath, D E Stover, A Hemdan, I Belinskaya, R M Steingart, Y Taur, M B Feinstein","doi":"10.1155/2015/204826","DOIUrl":"https://doi.org/10.1155/2015/204826","url":null,"abstract":"The aim of this study is to determine if COPD patients undergoing lung resection with perioperative β-blocker use are more likely to suffer postoperative COPD exacerbations than those that did not receive perioperative β-blockers. Methods. A historical cohort study of COPD patients, undergoing lung resection surgery at Memorial Sloan-Kettering Cancer Center between 2002 and 2006. Primary outcomes were the rate of postoperative COPD exacerbations, defined as any initiation or increase of glucocorticoids for documented bronchospasm. Results. 520 patients with COPD were identified who underwent lung resection. Of these, 205 (39%) received perioperative β-blockers and 315 (61%) did not. COPD was mild among 361 patients (69% of all patients), moderate in 117 patients (23%), and severe in 42 patients (8%). COPD exacerbations occurred among 11 (5.4%) patients who received perioperative β-blockers and among 20 (6.3%) patients who did not. Secondary outcomes, which included respiratory failure, 30-day mortality, and the presence or absence of any cardiovascular complication, ICU transfer, cardiovascular complication, or readmission within 30 days, did not differ in prevalence between the two groups. Conclusions. This study implies that perioperative β-blockers use among COPD patients undergoing lung resection surgery does not impact the rate of exacerbations. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2015 ","pages":"204826"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/204826","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34048555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden. 老年(≥70岁)非小细胞肺癌患者的化疗:瑞典卡罗林斯卡大学医院7年临床实践回顾性研究

Lung cancer international Pub Date : 2015-01-01 Epub Date: 2015-07-14 DOI: 10.1155/2015/317868

Hirsh Koyi, Gunnar Hillerdal, Olov Andersson, Karl-Gustav Kölbeck, Per Liv, Eva Brandén

{"title":"Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden.","authors":"Hirsh Koyi, Gunnar Hillerdal, Olov Andersson, Karl-Gustav Kölbeck, Per Liv, Eva Brandén","doi":"10.1155/2015/317868","DOIUrl":"https://doi.org/10.1155/2015/317868","url":null,"abstract":"An increasing proportion of cancer patients are aged >65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to demonstrate how elderly patients with NSCLC are treated in real-life, clinical practice. All patients aged ≥70 years with NSCLC at our department were reviewed retrospectively. In total, 1059 patients (50.8% of all NSCLC patients). Of these patients, 243 (22.9%) received chemotherapy, 164 (70.4%) of whom were treated with a platinum doublet using carboplatin. Second- and third-line chemotherapy were given to 31.4% and 13.9% of patients, respectively. Median overall survival was 289 and 320 days for male and female patients, respectively. Patients with performance status (PS) 0 experienced significantly better survival than patients with PS1 or PS 2: 410, 314, and 204 days, respectively. Age was of less importance, with patients aged 70-79 years versus those aged ≥80 years. Treatment of elderly NSCLC patients with chemotherapy is feasible if they have a good PS and appears to prolong survival. In this study, we found no significant differences in survival either between age groups or genders. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2015 ","pages":"317868"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/317868","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34130761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC. 非小细胞肺癌患者和非小细胞肺癌患者胸部组织样本中的重金属含量

Lung cancer international Pub Date : 2014-01-01 Epub Date: 2014-07-09 DOI: 10.1155/2014/853158

Jessica Q Tran, Alexandra Dranikov, Anita Iannucci, Walter P Wagner, Janine LoBello, Jeffrey Allen, Glen J Weiss

{"title":"Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC.","authors":"Jessica Q Tran, Alexandra Dranikov, Anita Iannucci, Walter P Wagner, Janine LoBello, Jeffrey Allen, Glen J Weiss","doi":"10.1155/2014/853158","DOIUrl":"https://doi.org/10.1155/2014/853158","url":null,"abstract":"Objectives. Environmental factors expose an individual to heavy metals that may stimulate cancer growth preclinically including non-small cell lung cancer (NSCLC) cells. Here, we examine the prevalence of four heavy metals present in postsurgical tissues from individuals with and without NSCLC. Materials and Methods. Thoracic tissue samples from two separate sample sets were analyzed for cadmium (Cd), arsenic (As), mercury (Hg), and lead (Pb) content. Results. In the first sample set, there was no significant measurable amount of Pb and Hg found in either NSCLC tissue or nonmalignant lung tissue samples. Cd was the most prevalent heavy metal and As was present in moderate amounts. In the second sample set, Cd was measurable across all tissue types taken from 28 NSCLC patients and significantly higher Cd was measurable in noncancer benign lung (n = 9). In the NSCLC samples, As was measurable in moderate amounts, while Hg and Pb amounts were negligible. Conclusion. Cd and As are present in lung tissues for patients with NSCLC. With existing preclinical evidence of their tumorigenecity, it is plausible that Cd and/or As may have an impact on NSCLC development. Additional studies examining the prevalence and association between smokers and nonsmokers are suggested. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2014 ","pages":"853158"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/853158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34130759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2